The Value of a Post-Treatment Whole Body Scan

Amdur, Robert J.; Mazzaferri, Ernest L.

doi:10.1007/0-387-25714-4_9

Cited by 3 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An I-131 whole body scan (RxWBS) can detect the presence of metastases in patients treated with high-dose I-131 therapy [7,8]. A recent study reported that a RxWBS after the first I-131 treatment resulted in a change in the disease stage in 8.3% and in the therapeutic approach in another 15% of patients [8].…”

Section: Introductionmentioning

confidence: 98%

Improved Detection of Lung or Bone Metastases with an I-131 Whole Body Scan on the 7th Day After High-Dose I-131 Therapy in Patients with Thyroid Cancer

Chong

Song

Min

et al. 2010

Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 98%

Improved Detection of Lung or Bone Metastases with an I-131 Whole Body Scan on the 7th Day After High-Dose I-131 Therapy in Patients with Thyroid Cancer

Chong

Song

Min

et al. 2010

Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…Diffuse homogenous hepatic uptake of 131I on an RxWBS without visible uptake by the remnant or residual tumor suggests hidden metastases [2]. Furthermore, according to Nakayama et al [5], increased hepatic uptake of 131I on RxWBS may predict disease-related progression. It is thought that diffuse hepatic uptake of 131I on RxWBS indicates that the liver metabolizes 131I-labelled fragments of thyroglobulin secreted by the tumor [6].…”

Section: Introductionmentioning

confidence: 99%

Does hepatic visualisation show residual/metastatic thyroid tissue in differentiated thyroid cancer?

Hasbek¹

2019

Ann Clin Anal Med

View full text Add to dashboard Cite

Aim: Diffuse homogen hepatic uptake in whole-body scan (WBS) after radioiodine remnant ablation (RRA) suggests that there is occult or visible remnant thyroid tissue and/or tumor tissue. It is thought that the reason is hepatic metabolization of radioiodine (131I) marked thyroglobulin fragments which are secreted by remnant/tumor tissue. The aims of this study were to investigate whether the hepatic visualisation after radioiodine remnant ablation showed the presence of metastatic or residual disease in patients with differentiated thyroid cancer and also to investigate whether early or late WBS after RRA (RxWBS) had an effect on the physiological hepatic uptake. Material and Method: 201 DTC patients were evaluated (F/M: 152/49; mean age: 49.61±13 years (range: 18-85 years)) who referred for RRA. The therapeutic 131I dose ranged from 100mCi to 200mCi. RxWBS was performed earlier (in 1-4th-day after RRA) in 106 patients (Group 1) and was performed later (in 5-9th-day after RRA) in 95 patients (Group 2). Results: Diffuse hepatic uptake were seen only in three patients (2.8%) and was not seen in 103 patients (97.2%) in Group 1. However, in Group 2 diffuse hepatic uptake was seen in 93 patients (97.9%) (p<0.05) and not seen only in 2 patients (2.1%). There is not a statistically significant relationship between the hepatic uptake and serum Tg, LT4 and TSH level. There is a statistically significant relationship between anti-Tg level and hepatic uptake. Discussion: Physiological diffuse hepatic uptake of radioiodine in WBS after RRA may not be seen during the early WBS. Thus, metastatic foci may be missed with early scanning. We conclude that RxWBS after RRA should be done in late period.

show abstract

“…Using I-131 therapeutic dose imaging to follow these cases could be useful [2,11]. However, low uptake of very high I-131 therapeutic doses (up to 200 mCi)* might occur with a stunning effect [12] especially if preceded immediately by a diagnostic scan.…”

mentioning

confidence: 99%

Comparison between Radioiodine Therapeutic and Diagnostic Whole Body Scans in Postoperative Differentiated Thyroid Carcinoma Patients Correlation with Serum Thyroglobulin Levels

Mahmood¹,

Al-Mohannadi²,

Ballani³

2017

LMJ

View full text Add to dashboard Cite

It has been reported that distant metastases are the main cause of death in patients with thyroid carcinoma [1,2]. The whole body I-131 scan has been reported to be an efficient tool to follow up thyroid carcinoma [3]. Posttherapeutic and diagnostic scans can be used to evaluate the presence of recurrent thyroid cancer or the presence of thyroid distant metastases. However, a higher image quality or better detection of additional lesions can be achieved in the therapeutic scan by a delayed imaging of 4-7 days [4,5]. Additional lesions could be seen in immediate posttherapeutic dose [6]. Minimizing the risk of recurrence and metastases can be achieved in patients with differentiated thyroid cancer undergoing high-dose I-131 [1,6]. Comparison between radioiodine therapeutic and diagnostic whole body scans in postoperative differentiated thyroid carcinoma patients : correlation with serum thyroglobulin levels. J Med Liban 2017 ; 65 (1) : 25-28.Al-Shammeri I, Mahmood S, Al-Mohannadi S, Ballani N. Comparaison entre la radioiodine thérapeutique et les scans corporels de diagnostic chez des patients souffrant d'un carcinome thyroïdien différencié en postopératoire : corrélation avec les taux sériques de thyroglobuline. J Med Liban 2017 ; 65 (1) : 25-28.

show abstract

The Value of a Post-Treatment Whole Body Scan

Cited by 3 publications

References 4 publications

Improved Detection of Lung or Bone Metastases with an I-131 Whole Body Scan on the 7th Day After High-Dose I-131 Therapy in Patients with Thyroid Cancer

Improved Detection of Lung or Bone Metastases with an I-131 Whole Body Scan on the 7th Day After High-Dose I-131 Therapy in Patients with Thyroid Cancer

Does hepatic visualisation show residual/metastatic thyroid tissue in differentiated thyroid cancer?

Comparison between Radioiodine Therapeutic and Diagnostic Whole Body Scans in Postoperative Differentiated Thyroid Carcinoma Patients Correlation with Serum Thyroglobulin Levels

Contact Info

Product

Resources

About